White Papers

1. Meeting The FDA's New Real-World Evidence Standards 5/27/2026

   FDA guidance is reshaping RWE strategy. Sponsors that build interoperable, audit-ready RWD infrastructure now will be best positioned for faster, defensible submissions.

2. The eCOA Iceberg 5/27/2026

   Understand the true cost of eCOA deployment, beyond software licenses, to reduce protocol risk, avoid operational bottlenecks, and protect study timelines and data quality.

3. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

   In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.

4. De-Risking The Neurology IND: Lessons From Early FDA Engagement 5/27/2026

   Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.

5. Faster Starts, Stronger Finish: Operational Excellence In NSCLC 5/22/2026

   In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.

6. How Adaptive Design Accelerates Early‑Phase NSCLC Development 5/22/2026

   Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

7. Rethinking Trial Access Through Trust-Driven Design And Local Collaboration 5/19/2026

   Locally embedded research models help sponsors reach underserved populations while reducing burden on patients and health systems alike.

8. Reduce Avoidable Protocol Amendments By Anticipating Operational Pitfalls 5/13/2026

   This report examines how amendment drivers vary across therapeutic areas and how those changes impact execution, patient burden, site workload, timelines, and study costs.

9. 5 Questions Sponsors Must Ask Before Selecting A Randomization Partner 5/12/2026

   Choose the right IRT partner for complex master protocols. Learn how adaptive randomisation expertise and flexible technology reduce disruption and keep trials execution-ready.

10. State of Materiovigilance: Gaps, Technology & Outsourcing 5/12/2026

    Explore how pharma and biotech companies are using AI, outsourcing, and new technologies to strengthen materiovigilance for complex drug-device products.